EVMN
EVMNHealthcareNASDAQBiotechnology · Last scanned Oct 26, 2026
Scan Results
Daily timeframeEVMN operates as a clinical-stage biotechnology company in the United States. The company carries a $185.1M market cap, placing it firmly in the micro-cap category. The company develops therapies that target key drivers of chronic inflammatory diseases, with initial clinical development programs focusing on chronic spontaneous urticaria, atopic dermatitis, and ulcerative colitis.
Market Cap
$185.1M
Beta
—
P/E (TTM)
—
P/E (Fwd)
-1.44
EPS (TTM)
$-3.75
EPS (Fwd)
$-3.54
ROE
-52.1%
ROA
-32.0%
Cash
$200.8M
Total Debt
$8.6M
Free CF
-$39.1M
52W Change
-74.8%
Annual Financials
Cash vs Debt
Where EVMN stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, EVMN finished 68.91% below its 150-day moving average ($16.95) and 71.26% below its 200-day moving average ($18.34). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is EVMN overbought or oversold?
At the October 20, 2026 close, EVMN's RSI(14) was 11.3, in oversold territory (below 30). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
EVMN holds $200.8M in cash against $8.6M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. Free cash flow is running at -$39.1M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of -52.1% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity.
The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence EVMN's trajectory.